Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Hangzhou Gensciences Biopharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New clotting factor aims to stop bleeding in severe hemophilia a Results expected Feb 2027 (estimated)
- New clotting factor aims to cut bleeding episodes in severe hemophilia a Results expected Mar 2027 (estimated)